Chemotherapy-induced Neutropenia

10
Pipeline Programs
4
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
3
1
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

BeyondSpring Pharmaceuticals
4 programs
2
2
PegfilgrastimPhase 31 trial
PlinabulinPhase 31 trial
PlinabulinPhase 21 trial
PlinabulinPhase 21 trial
Active Trials
NCT04227990CompletedEst. Jan 2019
NCT04345900CompletedEst. Apr 2018
NCT03294577UnknownEst. Sep 2025
+1 more trials
Teva
TevaIsrael - Petach Tikva
2 programs
1
1
NeugraninPhase 31 trial
BalugrastimPhase 2/31 trial
Active Trials
NCT00837265Completed334Est. Jun 2009
NCT01126190Completed381Est. Feb 2012
Myelo Therapeutics
Myelo TherapeuticsGermany - Berlin
1 program
1
Myelo001Phase 21 trial
Active Trials
NCT02692742CompletedEst. Nov 2017
T-Therapeutics
T-TherapeuticsUK - Cambridge
3 programs
3
GW003Phase 11 trial
GW003Phase 11 trial
Pegylated Recombinant Human G-CSFPhase 11 trial
Active Trials
NCT02643901CompletedEst. Oct 2016
NCT02156388CompletedEst. Dec 2015
NCT02725606UnknownEst. Sep 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BeyondSpring PharmaceuticalsPegfilgrastim
BeyondSpring PharmaceuticalsPlinabulin
TevaNeugranin
TevaBalugrastim
BeyondSpring PharmaceuticalsPlinabulin
BeyondSpring PharmaceuticalsPlinabulin
Myelo TherapeuticsMyelo001
T-TherapeuticsPegylated Recombinant Human G-CSF
T-TherapeuticsGW003
T-TherapeuticsGW003

Clinical Trials (10)

Total enrollment: 715 patients across 10 trials

NCT03294577BeyondSpring PharmaceuticalsPegfilgrastim

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Start: Oct 2019Est. completion: Sep 2025
Phase 3Unknown
NCT03102606BeyondSpring PharmaceuticalsPlinabulin

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Start: May 2018Est. completion: Feb 2021
Phase 3Completed
NCT01126190TevaNeugranin

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Start: Jun 2010Est. completion: Feb 2012381 patients
Phase 3Completed
NCT00837265TevaBalugrastim

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Start: Aug 2008Est. completion: Jun 2009334 patients
Phase 2/3Completed
NCT04227990BeyondSpring PharmaceuticalsPlinabulin

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Start: Nov 2017Est. completion: Jan 2019
Phase 2Completed
NCT04345900BeyondSpring PharmaceuticalsPlinabulin

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Start: Apr 2017Est. completion: Apr 2018
Phase 2Completed
NCT02692742Myelo TherapeuticsMyelo001

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

Start: Mar 2016Est. completion: Nov 2017
Phase 2Completed
NCT02725606T-TherapeuticsPegylated Recombinant Human G-CSF

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Start: Mar 2016Est. completion: Sep 2017
Phase 1Unknown
NCT02643901T-TherapeuticsGW003

Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects

Start: Sep 2015Est. completion: Oct 2016
Phase 1Completed
NCT02156388T-TherapeuticsGW003

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

Start: Aug 2013Est. completion: Dec 2015
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space